Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,292 total articles
Ruhi Ahmad Khan, Chief Business Officer at Caribou Biosciences (CRBU), sold 6,938 shares on February 24, 2026, for $1.96 apiece to satisfy tax obligations tied to restricted stock unit vesting. The filings show earlier acquisitions on February 20, 2026 — 45,000 shares at a reported value of $0 and options to buy 202,500 shares at $1.80 that vest mo…
Ameris Bancorp Chief Financial Officer Nicole S Stokes reported a nominal sale of company stock on February 24, 2026, alongside other equity movements tied to compensation and tax-withholding. The $5.4 billion regional bank also released fourth-quarter 2025 results that slightly beat EPS expectations but missed revenue estimates. Separately, the co…
Benjamin C. Singer, Procore Technologies’ Chief Legal Officer and Secretary, sold 6,938 shares of the company’s common stock between February 23 and February 24, 2026, for roughly $348,023 under a pre-existing 10b5-1 trading arrangement. The stock trades near its 52-week low and had seen a roughly 23% decline over six months. Procore also reported …
Palantir Technologies Chief Accounting Officer Jeffrey Buckley sold 4,646 shares of Class A common stock on February 20 and February 24, 2026, in automated transactions executed under a Rule 10b5-1 plan to satisfy tax withholding tied to vesting restricted stock units. The trades realized roughly $520,000 in proceeds. Palantir shares are trading ma…
Palantir Technologies Inc's CFO and Treasurer, David A. Glazer, disposed of 17,488 shares of Class A common stock on February 20, 2026, in a series of automated transactions to satisfy tax-withholding obligations tied to restricted stock unit vesting. The sales, carried out under a Rule 10b5-1 plan, totaled $2,331,782 based on prices between $132.0…
Palantir Technologies' Chief Technology Officer and Executive Vice President, Sankar Shyam, sold $22.5 million of Class A Common Stock on February 20, 2026, in several transactions. The same day he converted a large block of Class B shares to Class A and received restricted stock units upon vesting. The stock has been under pressure year-to-date, w…
Ryan D. Taylor, an officer at Palantir Technologies Inc (NYSE: PLTR), sold 20,338 Class A shares on February 20, 2026, receiving $2.67 million in proceeds. The disposition was filed on a Form 4 with the SEC and occurred while the stock trades down 27.5% year-to-date and around $128.82 per share. The company has announced a partnership with Rackspac…
ImmunityBio director Christobel Selecky sold 25,000 shares on February 23, 2026, for $10 apiece, generating $250,000. On the same day she exercised options to buy 25,000 shares at $2.98, a transaction worth $74,500. The sale was carried out under a Rule 10b5-1 plan. The company has reported substantial revenue growth for its cancer therapy ANKTIVA,…
Palantir Technologies CEO Alexander C. Karp sold $65.9 million worth of Class A common stock in a series of transactions on February 20, 2026, and completed several conversions of Class B shares to Class A. The stock is trading below the sales range and is viewed by one service as overvalued versus Fair Value, even as analysts upgraded the shares a…
Palantir Technologies director Stephen Andrew Cohen sold $43.7 million of Class A Common Stock on February 20, 2026 across a series of transactions. The company’s shares have fallen 27.5% year-to-date and trade at a high price-to-earnings multiple. Cohen also converted Class B shares to Class A and restricted stock units were exercised into Class B…
Barry J. Simon, a director at ImmunityBio, sold 175,000 shares of the company’s common stock in late February 2026 for roughly $1.78 million under a pre-arranged Rule 10b5-1 plan. The transactions occurred as the stock traded above its 52-week high amid substantial revenue growth for the company’s cancer therapy ANKTIVA and new distribution deals i…
KalVista Pharmaceuticals CFO Brian Piekos sold 1,767 shares on February 23, 2026, netting $27,506 at a weighted average price of $15.5668 per share. Earlier in the week he exercised options on 5,000 shares and converted 5,000 restricted stock units into common stock. The insider moves come as KalVista reports preliminary fourth-quarter 2025 revenue…
KalVista Pharmaceuticals Chief Medical Officer Paul K. Audhya sold 5,354 shares on February 23, 2026, generating about $83,344. The sale followed the exercise and conversion of 11,250 restricted stock units into common shares on February 21 and 22. KalVista's stock trades around $15.77, and the company reported preliminary global EKTERLY sales of r…
Nicole Sweeny, chief commercial officer of KalVista Pharmaceuticals (KALV), sold 3,975 shares of common stock on February 23, 2026, to satisfy tax-withholding tied to vested RSUs. The sale totaled about $61,878 at a weighted average price of $15.5668. The company reported preliminary fourth-quarter 2025 EKTERLY revenue of roughly $35 million, well …
Christopher Yea, Chief Development Officer at KalVista Pharmaceuticals (KALV), sold 4,347 shares on February 23, 2026, to satisfy tax-withholding obligations stemming from the vesting and settlement of restricted stock units. The transaction was non-discretionary, according to a Form 4 filing. Separately, KalVista reported roughly $35 million in gl…
KalVista Pharmaceuticals Chief Executive Officer Benjamin L. Palleiko sold 10,034 shares on February 23, 2026 to cover tax withholding obligations, realizing roughly $156,197. The company reported about $35 million in fourth-quarter 2025 revenue from its oral HAE treatment EKTERLY, contributing to approximately $49 million in full-year sales after …
Reddit Chief Operating Officer Jennifer L. Wong sold a combined $5.6 million of Class A Common Stock on February 24, 2026, through a series of transactions executed at prices between $141.82 and $147.47. The divestiture included shares sold directly and via the MorMa Trust, and followed a company withholding of shares to cover tax obligations. The …
Reddit Chief Technology Officer Christopher Brian Slowe sold $2.74 million worth of Class A Common Stock on February 23 in a series of transactions that followed option exercises and a recent award of shares. The insider activity coincides with robust fourth-quarter 2025 financial results for Reddit and comes against a backdrop of regulatory penalt…
Michael Warren Vostrizansky, a director at Neptune Insurance Holdings Inc (NP), purchased 23,000 shares of Class A Common Stock on February 20, 2026, investing $494,414. The buy occurred as the stock trades below the purchase price and following a wave of analyst upgrades spurred by better-than-expected fourth-quarter adjusted EBITDA and revised re…
Renee M. Bacon, senior vice president for sales and operations at Murphy USA Inc. (NYSE: MUSA), executed a sale of 2,844 shares on February 23, 2026, generating roughly $1.105 million. The transaction, recorded in a Form 4 filing with the Securities and Exchange Commission, leaves Bacon with a direct holding of 3,083.3 shares. Separately, Murphy US…
Director Milton C. Blackmore disclosed a set of transactions in Innospec Inc. (IOSP) during late February. On February 20, Blackmore sold 1,030 shares at $81.84 apiece for $84,296 and on the same day exercised options to acquire 1,030 shares at an exercise price of $44.18 for a reported total of $45,505. On February 23 he recorded the acquisition o…
Innospec INC director Larry Padfield completed a set of transactions in late February 2026 that included the sale of 1,030 common shares, the exercise of options for an identical number of shares, and the vesting of restricted stock units. The trades occurred as the specialty chemicals firm trades below a referenced fair value estimate and continue…
Honeywell International director Grace Lieblein sold 5,857 shares of common stock on February 23, 2026, for about $1.4 million and exercised options to acquire 7,777 shares the same day. The transactions occurred near the stock's 52-week high and come as the company faces valuation scrutiny and completes strategic moves including a reduced-price ac…
Judy Bruner, a member of Applied Materials Inc's board, sold a combined $1.49 million of company stock on February 23, 2026, through transactions executed by a family trust. The sales occurred with the share price trading near its 52-week top, while analysts continue to raise targets and the stock is described as appearing overvalued by InvestingPr…
Nadia Waheed, Chief Medical Officer at Ocular Therapeutix, sold 3,510 shares on February 20, 2026, to satisfy tax withholding tied to recently vested restricted stock units. The sale, disclosed in a Form 4 filing, followed a pre-arranged automatic instruction adopted in June 2024. The stock has been volatile amid positive Phase 3 SOL-1 data for AXP…
